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Introduction
A number of carcinogenic heterocyclic amines (PhIP, MeIQx, and DiMeIQx) are
produced from the condensation of creatinine, hexoses and amino acids during the
cooking of meat (1).   There are many variables that impact the production and
subsequent ingestion of these compounds in our diet.  Temperature, type of meat product,
cooking method, doneness, and other factors affect the quantity of these carcinogens
consumed by humans.  Estimates of ingestion of these carcinogens are 1-20 ng/kg body
weight per day (2).  Human case control studies that correlate meat consumption from
2well-done cooking practices with cancer incidence indicate excess tumors for breast,
colon, stomach, esophagus, and possibly prostate (3-5).
Genetic Susceptibility
Heterocyclic amines (HAs) are activated and detoxified through a number of
different pathways.  The initial N-oxidation at the exocyclic amino group, present in all
HAs, primarily occurs in the liver, and almost exclusively by cytochrome P4501A2 (6,
7).  Further activation is possibly by conjugating enzymes like N-acetyltransferase and
sulfotransferase to eventually give a very reactive nitrenium ion that theoretically binds to
the guanine of DNA at the C-8 position (8).  This resulting adduct then leads to mutations
and cancer if not removed by the nucleotide excision repair pathway.  If precursors to the
reactive intermediates can be removed from the cells by detoxification, then the amount
of DNA damage can be minimized.  UDP-glucuronysltransferase appears to fulfill this
role.  Although genetic variants in any of the activation pathways can have an impact on
the total amount of DNA damage, we believe a major influence on the whole pathway
and thus susceptibility to cancer is the ability to detoxify.  We have described here the
basics of this pathway (genes to protein products) and discussed the impact of variation
of the numerous UGTs on DNA damage and ultimately cancer.
UDP-glucuronosyltransferase
The elimination of many endogenous and xenobiotic chemicals from the body is
highly dependent upon UDP-glucuronosyltransferase (UGT)-dependent conjugation with
glucuronic acid.  Compared to other conjugating enzymatic reactions UGT conjugation is
3somewhat unique.  The most notable differences are the location of the UGT protein and
the atypical gene structure of one of the enzyme subfamilies.  Similar to the cytochrome
P450s, the UGTs have a wide and varied substrate selectivity and specificity.  This trait
makes them able to conjugate many types of chemical classes.  UGTs are widely
distributed among tissues making site-specific metabolism an important factor in UGT-
mediated conjugation.  Chemical inducers and repressors, as well as, genetic variation in
some UGT genes regulate UGT expression.  Furthermore, alterations in gene expression,
due to genetic polymorphisms, can have profound effects on glucuronidation capacity.
The metabolism of several chemical carcinogens, including the cooked-food carcinogen
2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP), can be influenced by the
differential expression of certain UGT isozymes.  This differential expression of UGT
isoforms can change the metabolic ratio between bioactivation and detoxification.  A
change favoring bioactivation, caused by decreased glucuronidation activity, would likely
lead to an increase in the susceptibility of potential tumor formation from carcinogen
exposure.
The metabolism of certain chemical carcinogens by UGT-mediated
glucuronidation is one of the central pathways in maintaining health. .  The structure,
function and especially regulation of specific UGTs all contribute to how chemical
carcinogens can be bioactivated or detoxified.  Differential glucuronidation capacity
affects the bioactivation of the cooked-food carcinogen PhIP.
4UDP-glucuronosyltransferase Biochemistry
The UGTs are a multigene superfamily of constitutively and inducible membrane
bound enzymes that participate in the biotransformation of many different chemical
compounds.  Glucuronidation is an especially important pathway for detoxifying reactive
intermediates from metabolic reactions, which otherwise can be biotransformed into
cytotoxic or carcinogenic species (9).  The UGTs catalyze the conjugation of glucuronic
acid to a nucleophilic substrate that increases the polarity of the substrate to facilitate its
excretion through the urine or bile (10, 11).  The sugar co-substrate for the reaction is
uridine 5’-diphosphoglucuronic acid (UDPGA), which is generated in the cytosol in a
series of reactions starting with glucose.  The rate-limiting enzyme in the UDPGA
synthetic pathway is UDP-glucose dehydrogenase, and is most likely an important factor
affecting the rate of glucuronidation (12).  The subcellular localization of the UGTs is
within the endoplasmic reticulum in a conformation such that the majority of the protein
is luminal.  This luminal localization results in the phenomenon of latency, possibly due
to the ER membrane acting as a diffusional barrier for substrate and cofactor access, and
metabolite and byproduct removal (13).
UDP-glucuronosyltransferase gene structure
The human UGT proteins are divided into two gene families, UGT1 and UGT2,
based on sequence homologies.  These families are further divided into three subfamilies,
UGT1A, UGT2A, and UGT2B.  The proteins range from 529 to 534 amino acids in length
for a molecular weight of 52-57 kDa, with several highly conserved regions that are
important for membrane targeting and activity.  The carboxyl terminus of all UGTs
5shares a high degree of similarity whereas the amino-terminal domain is divergent.  The
UGT1A family is located on chromosome 2 (2q37) and is derived from a single gene
locus composed of 5 exons (Figure 1).  The amino half of the gene (280 amino acids) is
encoded by one of thirteen exon 1 sequences that produce individual UGT1A proteins
(14).  Each unique exon 1 sequence is proximal to its own distinctive promoter.  Of the
thirteen exon 1 sequences, nine code for functional UGT proteins (UGT1A1, UGT1A3,
UGT1A4, UGT1A5, UGT1A6, UGT1A7, UGT1A8, UGT1A9, UGT1A10) and four
represent pseudogenes (UGT1A2p, UGT1A11p, UGT1A12p, UGT1A13p) (14, 15).  The
regulatory sequences flanking each of the exon 1 regions are thought to dictate the
individual expression profile of each UGT1A isoform (16).  The carboxyl terminus
sequence (245 amino acids) is identical for all UGT1A subfamily members and is
comprised of exons 2-5.  This gene structure is atypical among enzymes involved in
xenobiotic metabolism (12).  It has been proposed that the unique amino-terminal half of
each UGT protein codes for the specific substrate-binding domain while the common
carboxyl-terminal half codes for the UDPGA co-substrate binding domain (17, 18).  The
existence of the unique substrate binding domains provides for the large substrate
specificity and selectivity observed in the UGT1A proteins.  In contrast to the UGT1
family, the UGT2 genes are located on chromosome 4 (4q13) and are comprised of eight
individual structural genes (6 genes for UGT2B; 2 genes for UGT2A subfamilies).  Like
the UGT1A proteins, the UGT2B proteins share a high degree of similarity at the
carboxyl-terminal region and are divergent at the amino-terminal domain.  The UGT2B
proteins are primarily responsible for steroid metabolism (19).
6Substrate specificity and selectivity
The UGTs have wide and overlapping substrate specificities and selectivities.
The substrates include endogenous steroids, hormones, bilirubin, bile acids, dietary
constituents, and numerous xenobiotic drugs, environmental pollutants, and carcinogens.
Functional groups known to be conjugated include phenols and aliphatic alcohols,
carboxylic acids, primary, secondary and tertiary amines, and nucleophilic carbon atoms.
A listing of UGT glucuronidation activity toward specific substrate classes for each UGT
isozyme can be found in a review by Tukey and Strassburg (19).  Glucuronidation is
generally thought of as a detoxification reaction, however, there are examples were
glucuronide conjugation results in increased biological activity.  These include the N-O-
glucuronides of hydroxamic acids and the acyl glucuronides of carboxylic acids.  In
addition, several drugs are known to produce glucuronide conjugates that have
pharmacological or toxic activities higher than their parent compound.  Examples of
these include glucuronides of morphine, all-trans-retinol and all-trans-retinoic acid, and
natural and synthetic estrogens (reviewed in (12)).
Tissue distribution of UDP-glucuronosyltransferase
Expression of UGT proteins has been detected in multiple tissues, with the liver
being regarded as the site with the greatest glucuronidation capacity.  High levels of
activity have also been observed in the kidney, and intestine indicating a significant
capacity for extrahepatic glucuronidation.  Other tissues expressing UGT activity include
lung, olfactory epithelium, ovary, mammary gland, testis, and prostate (reviewed in (19)).
The mechanisms that determine the wide UGT tissue distribution and expression have yet
7to be determined.  In addition to having a wide tissue distribution, UGT proteins can be
preferentially expressed in different tissues.  The UGT1A gene locus in the liver codes for
UGT1A1, UGT1A3, UGT1A4, UGT1A6, and UGT1A9.  Expression of UGT1A7,
UGT1A8, and UGT1A10 is found exclusively in extrahepatic tissue, primarily in gastric,
colon, and biliary tissue, respectively.  Expression of the UGT1A locus in the colon is the
most diverse with gene transcripts detected for UGT1A1, UGT1A3, UGT1A4, UGT1A6,
UGT1A8, UGT1A9, and UGT1A10.  The differential expression of the UGT1A family of
enzymes demonstrates the importance of site-specific metabolism and substrate
selectivity of the UGT1A proteins.  Low expression of a particular UGT in a specific
tissue could alter the metabolism of a xenobiotic compound in that tissue, potentially
diverting it to pathways that would produce a more biologically active compound that
could bind proteins and/or DNA.
Gene regulation
Expression of UGT genes can be regulated by chemically mediated induction or
repression.  Studies have shown that human UGT1A1, UGT1A6, and UGT1A9 expression
is induced by dioxin via binding of the aryl hydrocarbon receptor (AhR) to a xenobiotic
response element (20, 21).  Upon ligand binding the AhR/ligand complex translocates to
the nucleus where it dimerizes with the AhR nuclear translocator (ARNT).  This
heterodimer complex binds to a dioxin response element which results in enhanced UGT
transcription and subsequent expression.  Other inducers include antioxidants such as
tertbutylhydroquinone and quercetin that can induce UGT1A6 (22).  UGT1A1 has been
shown to be up-regulated by 3-methylcholanthrene and oltripaz in human hepatocytes
8and by flavonoids in human HepG2 cells (23, 24).  Furthermore, the dietary
anticarcinogens coumarin, curcumin, α-angelicalactone, fumaric acid and flavones
caused an increase in the glucuronidation of 4-nitrophenol and 4-methylumbelliferone in
rat hepatic microsomes (25).
More recently the human orphan nuclear receptors, human pregnane X receptor
(hPXR) and constitutive androstane receptor (CAR), have been implicated in the
regulation of UGT genes.  Studies have shown that phenobarbital and rifampicin, which
are ligands for hPXR and CAR, can mediate UGT expression.  In human HepG2 cells it
was shown that CAR binds to a nuclear response element within the UGT1A1 promoter
and enhances UGT1A1 gene transcription.  This enhancement is increased by
phenobarbital and decreased by androstenol (an inhibitory ligand for CAR) (26).
Deletion analysis of the UGT1A1 promoter region resulted in the identification of a
regulatory sequence that conferred hPXR regulation of the UGT1A1 gene (27).  Western
blot analysis showed that both hPXR and CAR induce UGT1A1 and UGT1A6 activities.
In addition, transgenic mice that possess a constitutively activated form of hPXR,
demonstrated a significant increase in UGT activity towards steroids, carcinogens, and
enhanced bilirubin clearance.  Evidence is also suggests UGT1A1 and UGT1A6 are direct
transcriptional targets for hPXR (27).
In addition to chemical induction of UGTs, repression of UGT activity has been
reported for a number of chemical compounds.  The antibiotic novobiocin was shown to
inhibit UGT-mediated bilirubin conjugation in rats by disrupting Mg2+ complexes.  This
inhibition was dose dependent and caused hyperbilirubinemia in the animals, and was
reversible when novobiocin was removed (28).  In other studies, long chain acyl-CoAs,
9which are intermediates in fatty acid metabolism pathways, have been shown to be
excellent inhibitors of glucuronidation.  Both oleoyl-CoA and palmityl-CoA caused a
dose dependent inhibition of UGT activity in rat liver microsomes and hepatocytes.  This
inhibition was noncompetitive and occurred at physiological concentrations of acyl-CoAs
(29, 30).  This inhibition by fatty acid metabolites illustrates how complex the whole
organism detoxification can be for dietary constituents.  If this has physiological
significance, well-done meats with higher fat content will not only have higher HA
content but the detoxification pathways will be inhibited leading to increased DNA
binding and cancer.  Furthermore, significant down-regulation of hepatic UGT1A1,
UGT1A3, UGT1A4, and UGT1A9 has been reported in malignant hepatocellular
carcinoma and its premalignant precursor, hepatic adenoma, but not in benign focal
nodular hyperplasia (31).  This finding indicates that down-regulation of the UGT1A gene
is an early event in hepatocarcinogenesis.
Genetic variation
UGT activity can also be regulated by genetic variability.  Interindividual
expression patterns have been reported for all UGTs except UGT1A10.  This variation in
expression was observed only in extrahepatic tissue, whereas hepatic expression showed
no difference in the expression of UGT gene transcripts. (32-35).  Polymorphisms in
UGT1A1, UGT1A6, UGT1A7, UGT2B4, UGT2B7 and UGT2B15 have been reported.
These polymorphisms have been implicated as risk factors for certain clinical diseases
and cancers (19, 35-40). The most notable polymorphisms are variants in the UGT1A1
gene that result in significant down regulation of UGT1A1 activity.  UGT1A1 is involved
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in the glucuronidation of: estradiol, simple and complex phenols, several chemical
carcinogens, and is the only UGT isoform known to catalyze the glucuronidation of
bilirubin in humans (19, 41, 42).  Bilirubin is a toxic breakdown product of heme that can
accumulate in tissues resulting in jaundice if not eliminated through transport via albumin
binding or conjugation by UGT1A1.  At high serum levels, bilirubin can cross the blood
brain barrier and lead to fatal necrosis of neurons and glial tissue.  Therefore, down
regulation of UGT1A1 activity can result in an increase in serum levels of unconjugated
bilirubin which can lead to bilirubin toxicity.
In humans three forms of inheritable unconjugated hyperbilirubinemia exist.  The
most serious, although very rare, is Crigler-Najjar syndrome type I which is transmitted
as an autosomal recessive trait in humans and is characterized by an inability to form
bilirubin glucuronides.  This condition is caused by mutant coding regions in various
UGT1A1 alleles which results in either a lack of UGT1A1 production or the production
of a non-functional protein (reviewed in (19)).  The onset of Crigler-Najjar type I results
in early childhood death.  Crigler-Najjar syndrome type II is less severe than type I and is
characterized by having very low UGT1A1 activity (10% of normal activity).  This
condition can be treated with enzyme induction therapy using phenobarbital.  The most
common form of hyperbilirubinemia is Gilbert’s syndrome, which occurs, in 3-10% of
the general population.  This condition is characterized by chronic, mild
hyperbilirubinemia which is exacerbated by stress, infection, fasting or physical activity
(19).  Gilbert’s syndrome is characterized by an allelic variant in the UGT1A1 gene
which contains an additional (TA) dinucleotide repeat in the “A(TA)nTAA” box region of
the promoter. (43, 44).  Functional studies have shown that the reference UGT1A1
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activity is associated with six TA repeats (UGT1A1*1).  Increasing the number of TA
repeats leads to a decrease in the rate of UGT1A1 transcription (35).  The most common
variant allele contains seven TA repeats (UGT1A1*28) and is the polymorphism
associated with Gilbert’s syndrome (16).  This polymorphism results in hepatic bilirubin
UGT conjugation being reduced to about 30% of normal (13, 45).  There is evidence to
suggest that individuals with Gilbert’s syndrome may be at greater risk from toxicants
and carcinogens that are conjugated by UGT1A1 because their ability to detoxify these
compounds would be diminished (35).  For example, a recent study has reported a
correlation between the UGT1A1 “ATATAA” box polymorphism and a decreased ability
to glucuronidate and detoxify benzo[a]pyrene-trans7R,8R-dihydrodiol [BAPD(—)] in
human liver microsomes (46).  Although we have been primarily discussing HAs, PAHs,
such as BaP, are accumulated on the surface of meat when the meat is cooked on a
barbeque grill. As the fat drips onto the coals, it is then pyrolized to PAHs.  The PAHs
are then deposited on the meat from the smoke plume.  Clearly, dual exposure to both
classes of carcinogens is probably additive with respect to DNA damage, but specific
genetic variants as described above can attenuate the exposure.  Subjects possessing the
UGT1A1*28 allelic variant (which contains (TA)7 repeats) showed significant decreases
in UGT1A1 protein expression and BAPD(—) glucuronidation activity in liver
microsomes when compared to subjects having the wild-type UGT1A1(*1/*1) genotype.
Other significant polymorphisms include allelic variation in UGT1A6, UGT1A7,
UGT2B7, and UGT2B15.  UGT1A6 has been found to be polymorphic with at least four
alleles characterized by three single nucleotide polymorphisms (SNPs) in the coding
region (19, 47).  UGT1A6 catalyzes the conjugation of simple phenols and planar
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arylamines, as well as many drugs including antidepressants and β-adrenoceptor
blockers.  The UGT1A7 gene that is not expressed in liver is responsible for
glucuronidating many different drugs and toxicants, including several carcinogens,
contains 9 different variant alleles (16). One of the alleles (UGT1A7*3) is found in 17%
of the general population.  All the mutations in both the UGT1A6 and UGT1A7 genes are
associated with lower glucuronidation activity compared to the wild type genotype (16).
Both UGT2B7 and UGT2B15 catalyze the glucuronidation of steroid hormones, as well
as several classes of xenobiotic substrates (11).  Allelic variants have been identified for
UGT2B7 and UGT2B15 isozymes resulting in a histidine to tyrosine and an aspartic acid
to tyrosine amino-acid substitution, respectively (16, 48).  In vitro studies have reported
no difference in catalytic activity between the UGT2B7 and UGT2B15 reference alleles
and the variant alleles (49, 50).  In vivo studies have yet to be completed.
UDP-glucuronosyltransferase and cancer susceptibility
Polymorphisms in UGT genes have also been associated with a potential increase
in the susceptibility to certain forms of cancer due to a reduced capacity to detoxify
carcinogenic compounds.  Several chemical carcinogens have been shown to be
substrates for glucuronidation, including many primary amines, several BaPs, and some
heterocyclic amines (reviewed in (19)).  Studies have shown that a reduced
glucuronidation capacity can lead to an increase in bioactivation for these compounds.
For example, when UGT1A deficient Gunn rats were exposed to BaP, covalent binding to
hepatic DNA and microsomal protein was enhanced, and production of BaP glucuronide
conjugates were reduced when compared to rats with normal UGT1A activity (51).  In
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human tissue, glucuronidating activity towards benzo[a]pyrene-trans7R,8R-dihydrodiol
[BAPD(—)] was compared with liver microsomes from humans expressing UGT1A1*28
(Gilbert’s Syndrome) versus normal liver microsomes.  Results showed a significant
decreased in BAPD(—) glucuronide conjugate formation in the subjects possessing the
UGT1A1*28 genotype (46).   In another study, an over 200-fold interindividual
variability was observed in both the glucuronidation and covalent binding of BaP
metabolites in human lymphocytes exposed to BaP (52).  A decrease in BaP
glucuronidation activity correlated with both an increase in BaP covalent binding and
enhanced BaP cytotoxicity.  Reduced UGT activity can also alter the biotransformation
of carcinogenic heterocyclic amines that are found in the diet.
Heterocyclic amine carcinogens in food
Diet has long been associated with cancer etiology (53-55). This association may
be related to such nutritional factors as fat or fiber intake, antioxidant exposure, or
exposure to carcinogenic substances present in the diet.  Historically sources of
mutagens/carcinogens in food have been derived from pesticides and artificially added
chemicals such as food preservatives and coloring agents. In addition to synthetic
chemicals, naturally occurring mutagens can be present in certain foods as well.  These
include pyrrolizidine alkaloids which occur in many plant species, hydrazines found in
mushrooms, alkylating agents found in spice oils, and nitrites which produce
nitrosamines from the degradation products of proteins or other food components (56).  A
more recently discovered source of food-derived mutagens/carcinogens are those
produced during the cooking of food (57).  Carcinogenic compounds derived from
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cooking food include pyrolysis products which are formed at temperatures of 300°C to
600°C and low temperature  (<300°C) thermic mutagens which are produced in high
protein foods derived from muscle.  One of the first observations of the carcinogenic
potential of cooked-foods was made in 1939 by Widmark who reported malignant tumors
in the mammary glands of female mice chronically exposed to extracts of horse muscle
cooked at a temperature of 275°C (58).  It was not until the mid to late 1970s, however,
when better analytical techniques were developed that significant advances were made in
the study of dietary thermic mutagens.  These studies ultimately lead to the discovery of a
class of heterocyclic amines (HAs) that are formed during the cooking of foods that are
commonly consumed in a typical Western diet (57, 59, 60).  These compounds are part of
the amino-imidazoazaarene (AIA) class of HAs due to a common imidazole-ring
structure and exocyclic amine group (61) (Figure 2).  They are formed by the
condensation of creatinine with amino acids during the cooking of meat, under normal
household cooking conditions.  The concentration of HAs found in cooked meats can
range from less than 1 part per billion (ppb) to greater than 500 ppb depending on meat
type, precursor concentration and cooking method (1, 2).  In general, frying or grilling at
high temperatures for longer time periods will increase the amount of HAs in meats.
These AIA HAs are among the most potent mutagens ever tested in the
Ames/Salmonella mutation assay (57).  In rodents, these compounds produced tumors in
a variety of tissues including the liver, lung, intestine, breast, and prostate (62)  In
humans they have been shown to cause DNA adducts in multiple tissues (63-65).
Epidemiology studies have indicated an increase risk of colon tumors associated with HA
exposure from well-done red meat consumption (3, 66).
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Carcinogenicity of PhIP
Of all the HAs currently identified, PhIP is the most mass abundant and has been
detected at the highest levels in grilled or fried beef and chicken (2, 67).  PhIP has been
shown to be carcinogenic in both mice and rats.  Exposure to PhIP produced lymphomas
in the mesenteric lymph nodes, mediastinal lymph nodes and spleen of CDF1 mice
exposed to 400 parts per million dietary PhIP for 579 days (68), as well as hepatic
adenomas in neonatal mice (69).  In F344 rats PhIP produced high incidences of colon,
mammary and prostate carcinomas when administered at a concentration of 400 parts per
million in the diet for 365 days (4, 5).  PhIP has also been shown to induce DNA strand
breaks and sister-chromatid exchanges in Chinese hamster ovary cells (70, 71), and to
form DNA adducts in both rodent and human tissues (63, 72-75). In addition, intake of
PhIP from well-done red meat consumption has been associated with an increased risk
for breast cancer in women (76).  These findings, together with the relative abundance of
PhIP in cooked foods, indicate that PhIP may pose a significant risk to the development
of certain human cancers.
Metabolism of PhIP
The metabolism of PhIP involves both phase I and phase II pathways for
bioactivation and/or detoxification (Figure 3).  PhIP bioactivation is highly dependent
upon the hepatic cytochrome P4501A2 (CYP1A2) mediated N-hydroxylation to the
corresponding 2-hydroxyamino-1-methyl-6-phenylimidazo[4,5-b]pyridine (N-hydroxy-
PhIP) (6, 7).  In extrahepatic tissue CYP1A1 and CYP1B1 have also been reported to
16
activate PhIP (77).  N-Hydroxy-PhIP is subsequently esterified by phase II
sulfotransferases and/or acetyltransferases that generate the highly electrophilic O-
sulfonyl and O-acetyl esters, respectively. These esters are capable of heterolytic
cleavage to generate the reactive nitrinium ion which is considered the ultimate
carcinogenic species(78).  This reactive nitrinium ion is able to form DNA adducts,
mainly at the C8 position of guanine (8, 72, 79).  Other conjugating enzymes have also
been shown to further activate N-hydroxy-PhIP and bind DNA but are considered minor
contributors to PhIP bioactivation (78, 80).  N-Glucuronidation can compete with these
activation reactions resulting in the formation of the less reactive N-hydroxy-PhIP-N2-
glucuornide and N-hydroxy-PhIP-N3-glucuonide.  These compounds can be excreted
through the urine or bile, or can be transported to extrahepatic tissue where deconjugation
by β-glucuronidase, can occur leading to the re-generation of the reactive intermediate N-
hydroxy-PhIP (81, 82).  Detoxification of PhIP involves formation of the CYP450-
mediated non-reactive 2-amino-1-methyl-6-(4’-hydroxy)phenylimidazo[4,5-b]pyridine
(4’-hydroxy-PhIP).  This compound can undergo sulfotransferase- and/or
glucuronosyltransferase-mediated conjugation, producing more polar unreactive
compounds which are readily excreted (83, 84).  This pathway is more prevalent in
rodents than in humans because the rate of 4’-hydroxy-PhIP formation is much more
dependent on CYP1A1 than CYP1A2, and CYP1A1 is not expressed in human liver, the
site most responsible for PhIP hydroxylation (77, 85, 86).  PhIP can also form
nonreactive direct glucuronides at the N2 and N3 positions (87).
In humans, studies have indicated that CYP1A2 catalyzed N-hydroxylation and
subsequent UGT-mediated glucuronidation is quantitatively the most important pathway
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in the metabolism of PhIP.  When human volunteers were exposed to PhIP, N-hydroxy-
PhIP glucuronide conjugates accounted for approximately 60% of the total PhIP urinary
metabolites (88).  N-hydroxy-PhIP-N2-glucuronide was also the major metabolite in
human urine after consumption of a single cooked chicken meal (89).  Further
investigations have determined that the UGT1A subfamily of UGTs plays a major role in
the glucuronidation of PhIP (90-92).  Microsomes containing human UGT1A isoforms
were able to convert N-hydroxy-PhIP to both N-hydroxy-PhIP-N2-glucuronide and N-
hydroxy-PhIP-N3-glucuronide.  A more recent study has implicated UGT1A1 as the
primary UGT1A isoform responsible for PhIP glucuronidation (93).  Microsomal
preparations from UGT1A1 expressing baculovirus infected insect cells produced 5 times
more N-hydroxy-PhIP-N2-glucuornide compared to microsomes containing UGT1A4, the
next most active UGT protein.
UDP-glucuronosyltransferase and PhIP risk susceptibility
It is difficult to assess PhIP risk susceptibility in humans due to wide variations in
PhIP metabolism.  There are numerous factors that can influence metabolism which are
regarded as important determinants of individual susceptibility to the carcinogenic effects
of PhIP.  These include but are not limited to PhIP dose, variations in diet, species
differences in metabolism, and polymorphic distribution of PhIP-metabolizing enzymes.
High doses of PhIP, typically used in animal studies, can potentially saturate enzymatic
pathways which can divert PhIP to metabolic pathways that would not usually be used in
a low dose exposure.  Species differences in metabolism can also effect risk susceptibility
determinations.  In humans and dogs UGT-mediated N-hydroxy-PhIP glucuronidation is
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a major pathway in PhIP biotransformation, whereas in rodents this is a minor pathway
(Figure 1.4).  Polymorphic expression of PhIP-metabolizing enzymes can play a large
role in determining risk susceptibility.  These polymorphisms can arise from both
heritable and environmental factors (94).  Humans display a large interindividual
variation in the expression of CYP450 and several of the phase II conjugation enzymes
(reviewed in (95)).  Studies have shown that the polymorphic expression of certain UGTs
can lead to differential metabolism of both endogenous and exogenous substrates
including PhIP (13).  For example, when UGT1A deficient Gunn rats were dosed orally
with PhIP, a decrease in PhIP glucuronide levels in the urine of these rats correlated with
an increase in hepatic DNA adducts compared to control rats with normal UGT1A
activity (96).  PhIP glucuronides in the bile of UGT1A deficient rats dosed with PhIP
intravenously were also reduced compared to control animals (97).  Furthermore, when
Chinese hamster ovary cells were transfected with the human UGT1A1 gene a significant
reduction in PhIP-induced cytotoxicity and mutation induction was observed when
compared to control cells that did not contain the UGT1A1 gene (98).  These results
suggest that UGT1A1 plays a major role in the metabolism of PhIP by providing a
protective effect against PhIP induced toxicity and mutation induction, and that variations
in UGT protein expression can potentially alter the bioactivation of PhIP.
Summary
Since UGT-mediated N-hydroxy-PhIP-glucuronidation is such a prominent
metabolic step in the biotransformation of PhIP in humans, understanding the
mechanistic aspects of PhIP glucuronidation and identifying the specific UGT enzymes
19
involved, and their regulation, is especially important.  The failure to conjugate N-
hydroxy-PhIP by glucuronidation could lead to further activation by sulfotransferase
and/or acetyltransferase, resulting in highly reactive esters that can bind DNA, and
potentially cause mutations.  Furthermore, differential expression of UGT isoforms in
specific tissues can change the metabolic ratio between bioactivation and detoxification.
A change favoring bioactivation, due to decreased glucuronidation activity, would likely
lead to an increase in the susceptibility of potential tumor formation from PhIP exposure.
Knowing the glucuronidation capacity of the specific UGT isozymes involved in N-
hydroxy-PhIP glucuronidation, and understanding the role of UGT in PhIP metabolism
will allow for a better understanding of the overall bioactivation/detoxification
mechanisms of PhIP.  This will help in evaluating the individual susceptibility to the
potential cancer risks associated with exposure to PhIP.  It is hypothesized that
individuals with low levels of specific UGT proteins will have a diminished capacity to
detoxify PhIP, making them more susceptible to the deleterious effects from PhIP
exposure.
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Figure Legends
Figure 1.  Organization of the UGT1A gene locus, and an example of how different
UGT1A RNAs are processed.  Exons 2-5 are common to all UGT1A isoforms.  Exon 1
contains sequences that code for the divergent portion of each UGT1A protein,
represented by exons 1.1-1.13.  Transcription is initiated at promoters that flank each of
the exon-1 sequences.  The 5’ and 3’ consensus-splice sites are recognized by the
spliceosome and the intervening sequences are removed (Figure was adapted from Tukey
and Strassburg, 2000, Annu. Rev. Toxicol., 40, 581-616).
Figure 2.  Carcinogenic heterocyclic amines isolated from cooked foods. PhIP, 2-amino-
1-methyl-6-phenylimidazo[4,5-b]pyridine; DMIP, 2-amino-1,6-dimethylimidazo[4,5-
b]pyridine ; MeIQ, 2-amino-3,5-dimethylimidazo[4,5-f]quinoline; IQ, 2-amino-3-
methylimidazo[4,5-f]quinoline; MeIQx, 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline;
4,8-DiMeIQx, 2-amino-3,4,8-trimethylimidazo[4,5-f]quinoxaline.
Figure 3.  Overview of PhIP metabolism
Figure 4.  Species comparison of urinary PhIP metabolic profiles. A: human; B: dog; C:
mouse.
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